• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

byMinjee Kim
September 8, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

1. Adalimumab was efficacious when used simultaneously with wide-excision surgery for treatment of moderate to severe hidradenitis suppurativa (HS).

Evidence Rating Level: 1 (Excellent)

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that affects the hair follicles, and is characterized by painful nodules, abscesses, scarring, and tissue destruction. It usually occurs in the anogenital, axillary, and inguinal areas. Wide-excision surgery is the preferred treatment for this condition, due to its low recurrence rate. However, surgery is often done on the most serious lesions, whereas anti-inflammatory treatments may be used to treat other lesions on the body. The drug adalimumab is indicated for moderate to severe HS, and observational studies have demonstrated that using adalimumab simultaneously with surgery may lead to improved outcomes. The purpose of this phase 4, multi-centre randomized controlled trial is to further explore the efficacy and safety of adalimumab when used alongside surgery for HS. 206 patients were randomized evenly to receive either adalimumab or a placebo, starting from 12 weeks pre-surgery until 10 weeks post-surgery (beginning with 160 mg at week 0, decreasing to 80 mg at week 2, and finally 40 mg from then on). The primary outcome (assessed at 12 weeks post-surgery) was the number of patients achieving an HS clinical response (HiSCR), which is a 50% or greater reduction in total abscess and inflammatory nodule (AN) count, and no increase in abscess and draining fistula count, for all areas of the body. The results showed that the proportion of patients attaining an HiSCR was significantly higher in the adalimumab group than the placebo (treatment difference 14%, 95% CI 0-27%, p = 0.49). Additionally, the proportion of patients achieving an HiSCR other than at the surgical site was not significantly higher, at 12 weeks (treatment difference 13%, 95% CI -1 to 26%, p = 0.07), but was significantly higher at 24 weeks (treatment difference 20%, 95% CI 7-34%, p = 0.003). As well, the percentage of treatment-emergent and serious adverse effects was similar between both groups. Overall, adalimumab was shown to be an efficacious and safe drug to be used in conjunction with surgical treatment for moderate to severe HS cases.

Click to read the study in JAMA Surgery

Image: PD

@2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #anti-TNFa#HiSCR#HS#surgery#TNFaadalimumabdermatologyHidradenitis suppurativa
Previous Post

#VisualAbstract: Health wearable devices effectively promote bodyweight in overweight/obese individuals

Next Post

#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer

RelatedReports

Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers
StudyGraphics

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

April 26, 2022
#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers
StudyGraphics

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

April 12, 2022
#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
Next Post
#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer

#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer

Updated USPSTF guidelines favor treatment of mild gestational diabetes

Novel macrophage-regulating cream demonstrated superior therapeutic efficacy for the treatment of diabetic foot ulcers compared to standard absorbent dressing

The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor

Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.